Eloxx begins Alport syndrome drug trial

• Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the Phase 2b EXACT Study of exaluren.
• The trial is evaluating exaluren in patients with nonsense mutation Alport syndrome.
• Initial 16-week placebo-controlled data is expected in mid-2027, with final results planned by the end of 2027.

Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.

The study is focused on patients whose Alport syndrome is caused by nonsense mutations, a population without an FDA-approved treatment targeting the underlying genetic cause.

The initial placebo-controlled portion of the trial will evaluate patients over 16 weeks, with topline data expected in mid-2027 and final study results anticipated by the end of 2027.

Alport syndrome is a genetic kidney disorder that can lead to progressive kidney damage and kidney failure, particularly among patients with disease-causing mutations.

Eloxx said the EXACT Study represents continued development of exaluren for a rare disease population with limited treatment options.